These findings highlight the effects of weight-loss on biomarkers of MetS and OA through modulation of the adipokines leptin and adiponectin, although further studies are required to validate these by correlation with patient reported outcome measure (PROM) data. This evidence concerns the gene LEP and metabolic syndrome.